Loading...
Loading...
Deutsche Bank is raising its price target on Edwards Lifesciences Corp
EW to $68 after the company announced positive Cohort B data. This makes FDA approval more likely. It has an Hold rating on shares.
In the research note, Deutsche Bank writes, "The Cohort B data were positive and supportive of an ultimate FDA approval. In our view, the market view was for the trial to be good enough for approval, though it was better than likely expected as it hit superiority. At this time, we maintain our EPS estimates but raise our price target to $68 to reflect the lower risk now that Cohort B is behind us. There's still several data points ahead, which we'll assess and integrate into our future investment case."
Shares of Edwards Lifesciences gained almost 12% in after-hours trading yesterday to close at $66.55. It closed the regular session at $59.70.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in